It is a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency 1 The acquisition of the treatment for ...

Short-term GHRT was effective and safe without increased risk for cancers among real-world adults with growth hormone deficiency.

Researchers studying over 2,000 Ashkenazi Jewish centenarians uncovered two rare IGF-1 gene variants linked to exceptional ...

As the fitness boom took off, so did national gym chains like Gold’s Gym and Bally Total Fitness, which catered to ...

BARCELONA, Spain I April 1, 2025 I ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals with global rights for Increlex®, except for ...